Veru (NASDAQ:VERU) Announces Quarterly Earnings Results

Veru (NASDAQ:VERU) released its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%.

Veru Stock Performance

Shares of VERU traded down $0.04 during trading hours on Thursday, hitting $0.51. 2,887,448 shares of the stock were exchanged, compared to its average volume of 5,203,067. The stock’s 50-day moving average price is $0.72 and its two-hundred day moving average price is $0.77. Veru has a 12-month low of $0.37 and a 12-month high of $1.92. The company has a market cap of $74.36 million, a price-to-earnings ratio of -1.81 and a beta of -0.54.

Analysts Set New Price Targets

Several equities research analysts have weighed in on VERU shares. Oppenheimer reaffirmed an “outperform” rating and set a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Veru in a report on Thursday, January 2nd.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.